Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cypress Pharmaceutical has reached a settlement with Glaxo Group, a part of the GlaxoSmithKline group of companies, resolving all disputes between the companies related to Cypress's generic ranitidine oral solution products and Glaxo's Zantac syrup.
Subscribe to our email newsletter
Under the terms of the settlement, Glaxo has agreed not to assert its patent against Cypress’s new alcohol-free formulation of its generic ranitidine oral syrup. Cypress expects to launch the product immediately upon receiving FDA approval. As a result of the settlement, the parties filed a stipulation to dismiss their patent litigation pending in the US District Court of New York.